凯文·奥特森指导全球努力对抗耐抗生素的超级细菌

3.5亿美元用于新型抗生素和快速诊断。

抗生素是现代医学的基石，自1928年发现青霉素以来，它挽救了全世界数亿人的生命。 然而，今天，新出现的耐抗生素超级细菌正在超过治疗致命细菌感染的新药供应。 由于缺乏经济回报，制药行业几乎放弃了新抗生素的开发。 Both the 美国疾病控制与预防中心 and the 世界卫生组织 have identified antibiotic resistance as one of the greatest threats to public health worldwide.

As part of its sweeping effort to tackle the problem, the 美国卫生与公众服务部（HHS） announced on July 28, 2016, that it has selected the 波士顿大学法学院—and 凯文Outterson, BU professor of law—to lead a novel $350 million trans-Atlantic public-private partnership to spur the preclinical development of new antibiotics and antimicrobial rapid diagnostics and vaccines. The partnership is called Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X.

Read the full 但是今天 story here.